Monoreactive high affinity and polyreactive low affinity rheumatoid factors are produced by CD5+ B cells from patients with rheumatoid arthritis by unknown
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The CD5 (Leu-1, OKTI) molecule is typically expressed on the surface ofhuman
T lymphocytes (1). It is also present, albeit at lower density, on the surface ofsome
human B lymphocytes (2). Recently, we and others (3, 4) showed that CD5+ Blym-
phocytes constitute a discrete and major subset (N20% ofthe total circulating or
splenic B lymphocytes) within the normal human B cell repertoire. We also showed
that the antibodies produced by these cells are polyreactive. They bind to multiple
self-antigens such as the Fc fragment of homologous IgG, ssDNA, insulin (Ins)1,
or thyroglobulin (Tg) as well as exogenous antigens, as for example, tetanus toxoid
(TT) (3-6). Although these antibodies are polyreactive, they bind to a different ex-
tentto various antigens (6, 7). Similarly, in NZB and viable motheaten autoimmune
mice, the Ly-1' B lymphocytes (the mouse equivalent ofhuman CD5+ B cells) make
"autoantibodies" that are polyreactive (8, 9).
In patients with rheumatoid arthritis (RA) (4, 10, 11), preliminary experiments
suggest that the CD5+ B cell subset may be expanded, but there is little informa-
tion on the functional state ofthese cells or the nature of the antibodies produced.
Inthis report, using methodswerecently described(3, 7), we determined thenumber
of circulating CD5+ B lymphocytes in patients with RA and normal controls, in-
vestigated thefunctional features ofthesecells, andstudiedthe reactivity and affinity
of the antibodies produced. Our studies show that in RA the CD5+ B cell subset
is activated and expanded and produces two types ofrheumatoid factor (RF): one
that is polyreactive and has low affinity and the other that is monoreactive and has
high affinity for Fc fragment of IgG.
Materials and Methods
Preparation ofF~ripheralBloodB Lymphocytes.
￿
CirculatingBlymphocyteswere obtained from
28 healthy adult subjects (NIH Blood Bank Leukopheresis Research Program) and 13 RA
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patients. The RA patients were nine females and four males, age from 21 to 66 yr (mean,
48 yr), all had clinically active, classic seropositive RA, as defined by ARA criteria (12). Serum
RF titer ranged from 1 :80 to 1 :10,240. All patients were receiving nonsteroidal anti-inflam-
matory drugs at the time of the study; five were receiving prednisone (<10 mg per day), which
was not given in the 24 h before obtaining peripheral blood; two were receiving gold salts,
and four were receiving low-dose methotrexate weekly. Enriched PBMC fractions were ob-
resis and fractionated through lymphocyte separating medium (Litton
netics, Kensington, MD) (13). T lymphocytes and monocytes were removed as described
(13, 14). The remaining mononuclear cell fraction contained 40-50% B cells, <1% T cells,
<1% monocytes, and a variable amount of NK cells (3, 13, 14). These cells are referred to
here as "enriched B cells."
Flow Cytometry Studies.
￿
Enriched B cells (106) in 0.1 ml ofice-cold PBS containing 1 % BSA
(BSA-PBS) were reacted with phycoerythrin (PE)-labeled Bl mouse mAb to CD20 (PE-BI
mAb, IgG2a, Coulter Immunology, Hialeah, FL) or biotinylated mAb to CD5 (anti-Leu-1
mAb, IgG2a, Becton Dickinson & Co., Mountain View, CA) or both reagents. Cell surface
receptors for the Fc portions ofIgG were blocked usingnormal human serum (1% final con-
centration). Cell-bound biotinylated antibody was detected by using FITC-avidin (Sigma
Chemical Co., St. Louis, MO) (1.5 pg/106 cells). Negative control samples consisted of similar
cells reacted with a PE-labeled mAb and a biotinylated mAb of the same isotype (IgG2a,
Becton Dickinson & Co.), but with irrelevant specificity, and then with FITC-avidin. The
cells were analyzed with a FACS (model 440, Becton Dickinson & Co.) equipped with an
argon laser (3, 6). Events (35,000 per sample) were collected and analyzed usinga Consort
40 system (Becton Dickinson & Co.). Among red fluorescent (CD20') cells, those also dis-
playing green fluorescence were designated as CD5' B cells. Results of one-color analysis
were depicted as histograms and two-color analysis data were depicted as contourgrams (14).
The threshold of positivity was established on the basis of the analysis of negative control
samples. CD5' and CD5- B cells were characterized for their forward and 90° light scat-
tering (amplified in a linear fashion), and results were depicted in three-dimensional con-
tourgrams. When required, double-fluorescent (CD20'/CD5') and red-fluorescent only
(CD20*/CD5- ) cells were gated and sorted as CD5' and CD5- B lymphocytes, respectively
(3). Total CD20', including both CD5' and CD5', cells were sorted as unfractionated B
cells (3). Thedegree of selectivity achieved in the sorting procedure was assessed asdescribed (3).
Cell Proliferation and Ig Production Studies.
￿
Sorted CD5' and CD5- B lymphocytes were
washed twice with RPMI 1640 medium (Biofluids, Inc., Rockville, MD) containing 10%
FCS (Gibco Laboratories, Grand Island, NY), L-glutamine (2 mM), penicillin (50 IU/ml,
and streptomycin (50 pg/ml) (FCS-RPMI). These cells were distributed (20,000/well) in qua-
druplicate cultures in 96-well U-bottomed plates (Nunc, Hazleton, Denver, PA), in the pres-
ence or absence of 105 syngeneic irradiated (1,800 rad) PBMC as feeder cells, and cultured
in 5%o C02 atmosphere at 37°C. [3H]methylthymidine ([3H]TdR; NEN, Boston, MA,
2gCi/microculture well) was added to different quadruplicate wells on days 1, 2, 3, and 5.
On days 2, 3, 4, and 6, fluids and cells were harvested from different quadruplicate sets for
Ig titration and [3H]TdR incorporation.
Infection by EBV and Culture ofB Cells.
￿
Unfractionated, CD5' or CD5- B cells were in-
fected with EBV (3, 13, 14) and then distributed at different doses in 96-well round-bottomed
microculture plates. The wells contained 105 syngeneic or allogeneic irradiated PBMC (pre-
usly incubated in FCS-RPMI for 2 h at 37°C and then washed four times with warm
FCS-RPMI to remove cytophilic Ig) as feeders. The microcultures were
'
￿
humidified atmosphere supplemented with 57lo C02. At the desired
were harvested for the investigation ofIg content and the different antigen-
ed at 37°C
ids
ng activities.
Titration of Ig and Ig with Different Antigen-binding Activities.
￿
IgM, IgG, or IgA concentra-
ns were determined using ELISAs similar to those previously described (3, 7, 13) using
polystyrene plates (Immulon 2 ; Dynatech Corp., Alexandria, VA) coated with goat F(ab')2
fragment to human Ig (M + G + A) (Organon Teknika-Cappel, West Chester, PA). Horse-
radish peroxidase-conjugated affinity-purified F(ab')2 fragments to human R, ti, or a Ig H
chain (Organon Teknika-Cappel) were used as specific probes and the amount of bound horse-
radish peroxidase-conjugated probe was measured as absorbance at 492 nm usingan auto-mated ELISA reader (Titertek Multiscan Plus; Flow Laboratories, Inc., McLean, VA). Dose-
dependent binding curves for IgM, IgG, and IgA were constructed and used as references
(3, 13). IgM, IgG, and IgA to various antigens were titrated using antigen-specific ELISAs
as described (3, 7, 13). Plates were coated with 5 pg/ml of purified human IgG Fc fragment
(52,000 mol wt), purified human IgG,, IgG2, IgG3, IgG¢ (Calbioehem-Behring Corp., San
Diego, CA), purified F(ab`)2 fragment of human IgG, ssDNA, or purified human Tg, 1.5
pg/ml of purified TT, or 2.5 pg/ml of recombinant human Ins (a gift from Lilly Research
Laboratories, Indianapolis, IN), prepared as described (3, 7, 13). Alkaline phosphatase-con-
'° ' goat F(aV)2 fragments to x and X L chains (Sigma Chemical Co.)
were used to detect Ig L chains. A cocktail ofthree mouse mAbs to human IgG Fab! fragment
(ICN Biomedicals, Inc., CostaMesa, CA) was used to detect IgG to IgG Fc fragment. Refer
ence binding curves were constructed using antibodies to IgG Fe fragment, ssDNA, Tg, Ins,
and TT (13). The lower limit of sensitivity, corresponding to the threshold oflinear detecta-
bility, of IgM-, IgG-, and IgA-, or antigen-specific ELISAs was 5 ng Ig/ml.
Preparation ofHuman Monoclonal B CellLines and Construction ofCell Hybrids by Somatic Hybrid-
ization Techniques. Monoclonal EBVtransformed B cell lines, selected for productionof IgG
Fc fragment-binding antibodies, were established using sorted CD5' B cells from RA pa-
tients, as described (7). Some of those clones were stabilized by fusion with 173136 cells, a
human-mouse heterohybrid, as described (7). The resulting EBVtransformed B cell hybrids
were expanded in selection medium and sequentially cloned at 0.5 cell/well (7). Clones were
amplified and the mAbs produced separated as described (7).
Competitive InhibitionStudies.
￿
Competitive inhibition studies of the binding of human mAb
to solid-phase Fc fragment by the homologous or heterologous soluble ligands were performed
as described (7). The dissociation constants (Kd) of the mAbs for IgG Fc fragment were cal-
culated according to Friguet et al. (15). This method has been successfully applied to the
calculation of Kd in antigen-antibody systems involving multivalent linkages (7, 16, 17).
1981
Characterization ofPeripheral Blood CD5 B Lymphocytesfrom Normal Subjects andPa-
tients with RA. The percentage of CD5* B cells in the peripheral circulation of
normal subjects and patients with RA was determined by dual-color fluorescence
flow cytometry. Enriched peripheral blood B lymphocytes were reacted with PE-
labeled mAb to CD20, biotinylated mAb to CD5, subsequently stained with FITC-
avidin, and then applied to the FAGS for analysis. Typical contour maps derived
are shown in Fig. 1, A-H. Evaluation by this method of 28 healthy subjects and 13
patients with RA revealed that 18.0 t 4.7% (mean value t SD; range: 9.2-24.4)
and 37.4 ± 10.6% (range: 22.1-54.5) of the total B lymphocytes (CD20+ cells),
respectively, were C135' .
CD20+ /CD5+ and CD20+/CD5- lymphocytes were then investigated for their
light-scattering properties and representative results are depicted in Fig. 1, I, J, M,
and N. In cytofluorometric studies, the amplitudes of the forward and side light
scatter signals are considered proportional to the size and the internal complexity
of the cell, respectively (18). Scatter analysis revealed that the CD5- B lymphocytes
were homogeneous and small in both healthy subjects and patients. In contrast, >45%
of the CD5+ B lymphocytes from RA patients were large (Fig. 1 N) as compared
with 6% of the CD5+ B lymphocytes from healthy subjects (Fig. 1 J). To measure
spontaneous proliferation and Ig secretion, CD20+ /CD5 + and CD20+ /CD5- B
lymphocytes then were sorted and collected as two separate fractions. Reanalysis
of the lymphocytes sorted as CD5+ and CD5' showed that these cells fell back
within the coordinates respectively established for the sorting procedure (Fig. 1, K,1982
￿
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FIGURE 1 .
￿
Identification, light scattering analysis, and sorting of CD5* B cells in healthy sub-
jects and RA patients . Data are depicted as computer-derived contourgrams obtained from the
cytofluorometric analysis ofenriched B lymphocytes . Countourgrams shown here are represen-
tative examples ofthe patterns observed for individuals of the two groups studied . Enriched B
lymphocytes from healthy subjects or RA patients were reacted with : biotin-labeled IgG2amAb
and PE-labeled IgG2amAb (both with irrelevant specificity) and then FITC-avidin (t1 and E) ;
biotin-labeled mAb toCD5 (Leu-1) and then FITC-avidin (B and F) ; PE-labeledmAb to CD20
(C and G) ; biotin-labeled mAb to CD5, PE-labeled mAb to CD20, and then FITC-avidin (D
and H) . Double-(red and green) fluorescent (CD20'/CD5*) cells represent CD5* B lympho-
cytes . These cells (right dotted rectangle), and their CD20* /CD5 - counterparts (left dotted rectangle),
were sorted as CD5* andCD5- B lymphocytes, respectively (D and H) . Contourgrams derived
from the analysis of the B cells sorted as CD5- and CD5* are depicted in K and O, and L and
P, respectively. Corresponding insets contain the profiles of the relative green fluorescence inten-
sity of these sorted cell fractions (x-axis is relative green fluorescence intensity andy-axis is rela-
tive cell number) . Forward (x-axis) and side (y-axis) light scattering analysis ofCD5- and CD5*
B cells, are shown in I and M, andJ and N, respectively .L, 0, and P). The sorted CD5' and CD5- B cells then were cultured without added
stimulus. NeitherCD5' nor CD5- B cells from any ofthe healthy subjects showed
significant [3H]TdR incorporation over a 6-d period (Fig. 2A). In contrast, CD5+ ,
but not CD5- , B lymphocytes from each ofthe patients with RA displayed a high
rate ofspontaneous [3H]TdR incorporation when cultured under identical condi-
tions (Fig. 2 B).
High rates of spontaneous RF production have been reported in culture fluids
ofcirculating PBMC from RA patients (19). To determine whether CD5' B cells,
CD5- B cells, or both were responsible for this spontaneous Ig secretion, the
amount ofIgM, IgG, and IgA produced in the microcultures seeded in the above
experiment (Fig. 2) was determined. In healthy subjects, neither CD5' nor CD5`
B lymphocytes spontaneously produced significant amounts of Ig, even after 6 d
of culture (Fig. 3, A-C). In contrast, unstimulated CD5+ , but not CD5- , B cells
frompatientswith RAproducedlarge amountsofIgM, IgG, and IgA(Fig. 3, D-F).
Moreover, most ofthe Ig spontaneously produced by CD5' B cells from RA pa-
tients bound to the IgG Fc fragment (not shown).
To further investigate their antibody-producing potential, lymphocytes from 18
healthy subjects and 13 patients with RA were sorted into CD5' and CD5- frac-
tions, infectedwith EBV and cultured at 1,000/well, inpresence ofirradiated PBMC
feeders. After 4 wk, total IgM, IgG, and IgA concentrations were measured in the
supernatants ofthese microcultures. CD5+ B cells from RA patients produced 7,460
t 578, 162 t 43, and66 t 16 ng/microculture (meanvalue t SDof184 microcul-
tures) of IgM, IgG, and IgA, respectively. These amounts were not significantly
different from those produced by CD5- B cell microcultures from the same sub-
jects (5,953 t 469, 287 t 51, and 68 t 12 ng/microculture, respectively; mean
value t SDof184 microcultures). Comparable values were obtained whenthe amounts
of IgM, IgG, and IgA were measured in the microcultures seeded with CD5' or
CD5- B cells from healthy subjects (not shown) .
The binding activities ofthese Ig to TT (an exogenous antigen) and IgG Fcfrag-
ment (a self-antigen)are shown in Fig. 4. In both normal controls and patients with
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FIGURE 2.
￿
Spontaneous proliferation
of CD5' B cells from RA patients.
Approximately 2 x 104 purified CD5*
(solid circles) or CD5- (open circles) B
cells from four healthy subjects and five
RA patients were seededin quadrupli-
cate microcultures. [3H]TdR was
added on different days and 24 h later
the degree ofcellular incorporation was
measured. Circles are mean values of
incorporated [3H]TdR and vertical
bars are SE.1984
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FIGURE 3.
￿
Spontaneous Ig secretion by CD5* Bcells fromRA patients. Fluids from microcul-
turesof Fig. 2 were tested for their IgM, IgG, and IgA content. Circlesare mean values of the
concentrations of IgM, IgG, and IgA produced in 0.2 ml by 2 x 10¢sorted CD5* (solid circles)
or CD5- (open circles) Bcells from four healthy subjects (A-C)and five RA patients (D-F). Ver-
tical bars represent SD.
RA, virtually all cells producing antibodies (IgM, IgG, and IgA) to IgG Fc frag-
ment segregated with the CD5' B lymphocyte subset (Fig. 4 A). Cells producing
IgM antibodies to TT also segregated primarily with the CD5' B subset, but cells
producing IgG and IgA antibodies to TT segregated with the CD5" B cell subset
(Fig. 4 B).
Construction ofMonoclonal Cell Linesfrom CD5' B Lymphocytes and Characterization of
themAbs they Produce. To studythe fine specificity ofautoantibodies to IgG Fc frag-
ment, EBVtransformed B cell lines were generated using purified CD5' B cells
from three different RA patients. After three sequential cloning steps, 18 EBV
transformed B cell lines producing RF were obtained and the antigen-binding ac-
tivity ofthe monoclonal RFs were investigated using ELISAs with a panel ofself-
and non-self antigens. As shown in Table I, the monoclonal RFs could be divided
into two groups based on their antigen-binding reactivity. Eight mAbs (seven IgM
and one IgA) were polyreactive; they bound not only to the IgG Fc fragment, but
also to the four other antigens tested. The other 10 mAbs (five IgM and five IgA)
were monoreactive and bound efficiently only to IgG Fc fragment. In these experi-
ments (Table I), we preferentially selected for B cells producing monoreactive REA
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Production ofIgM,
IgG, and IgA antibody to IgG
Fc fragment (A)or to TT(B)by
different subsets of B cells.
Fluids from microculturesseed-
ed with 1,000 or 2,000 EBVin-
fected CD5', CD5-, or un-
fractionated B cellswere tested
forthe twoantigen-binding ac-
tivities. Each dotrepresents an
individual microculture and
-100 microcultures from each
group were tested. Data were
derived from two healthy sub-
jects and two RA patients and
arerepresentative oftheresults
consistently obtained from these
groups of subjects.
In RA, cellscommittedto the production of monoreactive RF were about one-tenth
as frequent as those committed to the production of polyreactive RE Thus far, in
healthyindividuals, we could notdetect any circulating B cell committed to theproduc-
tion of monoreactive RE
The multiple antigen-binding capacities of polyreactive RFs were further
documented in experiments in which each antibody was tested at different concen-
trations. All polyreactive RFs bound in a dose-dependent fashion, but to different
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TABLE I
Antigen-binding Activity, of mAbs Produced by EBV-transformed CD5+
B Lymphocytes from RA Patients
Antigen-binding activity expressed as absorbance at 492 nm. Threshold ofposi-
tivity was 0.1 . Positive values are underscored.
$ Fc fragment of IgG was used as selecting antigen for the generation of these
clones.
S Monoclonal cell lines stabilized by somatic cell hybridization .
degrees, to each of theantigens tested . The binding curves ofthree typical polyreac-
tive RFs and three typical monoreactive RFs are shown in Fig. 5, A-C and D-F,
respectively. The specificity of the monoreactive RFs for the IgG Fc fragment was
further supported by their inability to bind to the purified F(ab')2 portion of IgG
and their comparable ability to bind to the Fc fragment of different IgG subclasses
(i.e., IgG1, IgG2, IgG3, and IgG4) (not shown).
Thebinding activity of polyreactive and monoreactive RFswasstudiedin greater
depth by competitive inhibition experiments (Figure 5, A'-C, and D'-F') in which
the binding ofa given RF to solid-phase IgG Fc fragment was measured in the pres-
ence and absence of solublehomologous (i.e., IgGFc fragment) or heterologous an-
tigens (i.e., ssDNA, Tg, Ins, or TT). The binding of polyreactive RFs to solid-phase
IgG Fc fragment was inhibited in a dose-dependent fashion not only by the soluble
Fc fragment itself, but also, and with even higher efficiency, by some of the other
soluble ligands tested (Fig. 5, A'-C'). The binding of monoreactive RFs to solid-
phaseIgG Fc fragment also was inhibited in adose-dependent fashionby the soluble
Fc fragment, but not by any of the other soluble heterologous antigens, even at the
highest concentrations tested (Fig. 5, D'-F').
The competitive inhibition experiments enabled us to calculate the Kd of RFs for
IgG Fc fragment (7, 15). The Kd values of polyreactive RFs were in the range of
10' mollliter (Table II). In contrast, the Kd values of monoreactive RFs were ti100
Monoclonal RFl
H
chain
L
chain Fc
Antigen-binding
ssDNA Tg
activity'
Ins TT
274.RA.5 .1 w K 0.850 0.450 0.675 0.640 0.254
274.RA.F115 u is 0.340 0.331 0.344 0.523 0.715
274.RA.31 yi x 0.315 0.215 _0.720 0.520 0.430
274.RA.14 w X 0.230 0.620 0_ .240 0.170 0.414
275.RA.2 .7 u x 0.540 0.710 0 .375 1 .076 0.303
291 .RA.22 .1 u X 0.215 0.223 0.890 0.456 0.159
291 .RA.3.6 1A K 0.890 0.560 0 .785 0.459 _0._359
274.RA.5.5 a K 0.514 0.155 0.239 0.215 0.317
27CRA.15 .1 u K 1 .353 0.045 0.038 0.044 0.027
27CRATO u X 1 .098 0.042 0.059 0.037 0.067
274.RA.F5s u K 1 .450 0.049 0.044 0.048 0.055
275.RA.11 w K 1 .116 0.037 0 .066 0.036 0,045
291 .RA.5 .2 w 7. 1 .229 0.037 0.047 0.073 0.039
27CRAT1§ a Ic 1 .008 0.071 0.024 0.087 0.041
274.RA.5.3 a 1C 0.987 0.030 0 .023 0.045 0.033
274.RA.3.3 a K 0.875 0.043 0.054 0.054 0.032
291 .RA.7.2 a l _1 .32_1 0.077 0.033 0.024 0.043
29LRA.8.7 a K 0.779 0.065 0.043 0.032 0.054BURASTERO ET AL .
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Dose-dependent binding ofpolyreactive andmonoreactive RFs(A-C andD-F, respec-
tively) to solid-phase IgG Fc fragment (O), Ins ("), ssDNA (A), Tg (A), andTT (0) . Dose-
dependent inhibition ofbinding ofpolyreactive and monoreactive RFs(A-C andD'-F, respec-
tively) to solid-phase IgG Fc fragment by soluble homologous (Fc fragment) and heterologous
(ssDNA, Tg, Ins, or TT) antigens . Samples of each soluble antibody (0 .2 pg) were incubated
with increased concentrations (0.1-200 pg) of soluble IgG Fe fragment (O), ssDNA (A), Tg (A),
Ins ("), or TT (N) . After 18 h, the mixtures were transferred into ELISA plates coated with
IgGFc fragment and theamount ofantibody bound tothe solid phasewasmeasured.Thebinding
ofeach antibody in the presence of soluble ligand is expressed as percentage of the binding ac-
tivity measured after incubation of thesame antibody under identical conditions but in the ab-
sence ofsoluble ligand (100% binding activity) . This corresponded in each case to at least0.400
absorbance at 492 nm (range, 0.400-0.800).
19871988
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TABLE II
Dissociation Constant (Kd, mol/liter) of RFs Generated from
CD5' B Cells of Patients with RA
Experimental conditions for the determination of Kd are described in the legend
to Fig. 5. The mol wt of IgG Fc fragment was 52,000.
times lower, in the range of 10-7 mol/liter. Other polyreactive and monoreactive RFs
recently isolated gave similar values (not shown).
Discussion
RFs are autoantibodies directed against determinants on the constant portion of
the IgG Hchain (20). They are present at high titer in sera and synovial fluids of
patients with RA and are thought, but have not been proven, to be relevant to the
pathogenesis ofthis disease. Circulating antibodies (mainly IgM) with RRbinding
activity can also be detected in healthy subjects and their titer rises in the course
ofviral, bacterial, and parasitic infections (21, 22) or during immune response to
exogenous antigens (23). Recent studies (3, 4, 6, 7) showed that in healthy subjects
virtually all the precursors of the RRproducing B cells belong to the CD5' B cell
subset. Moreover, these RFs are polyreactive and bind to a number ofdifferent self
(e.g., ssDNA, Ins, Tg, etc.)and non-self(e.g., TT andbacterial LPS) antigens (6, 7).
The present work and recent reportsfrom otherlaboratories (4, 10, 11) show that
the number ofCD5' B cells are increased in patients with RA. In addition, we show
here that many ofthe CD5+, but not the CD5", B cells from RA patients are acti-
vated, spontaneously proliferate, and secrete Ig with RF activity. In contrast, studies
in progress (Burastero et al., in preparation.) indicate that CD5' B cells from pa-
tients with SLE are not increased in number and do not spontaneously proliferate
in vitro, suggesting that different mechanisms are operative in SLE and RA. Al-
though EBV has been suggested as a possible factor in the pathogenesis ofRA (24,
25), immunofluorescence and in situ DNA hybridization onthespontaneouslyprolifer-
ating CD5' cells has failed to show any evidence of EBV infection (unpublished
data).
In addition to the polyreactive RFs produced by CD5' B cells, the present study
shows that some CD5' B cells from RA patients produce monoreactive high affinity
RFs. The dissociation constant of these monoreactive RFs is -10-1 mol/liter. In
contrast, affinity values (Kav) previously reported (26) as characteristic ofhuman
RFs ranged between 103 and 105 liters/mol. This is compatible with the Kd values
ofour polyreactive RFs from both normal subjects (7) and patients with RA, but
lower by a factor ofat least 100 as compared with the monoreactive RFs from CD5'
cells ofRA patients. Thus, we conclude that in RA patients two types of RFs are
mAb H chain L chain Kd for IgG Fc fragment
274.RA.F11 w X 4.0 x 10 -5
274.RA.14 u is 3 .8 x 10 -5
274.RA.31 u is 2.3 x 10 -5
274.RA .F4 u is 6.0 x 10 -1
274.RA.F5 u K 3.5 x 10 -7
274.RA.F1 a K 2.0 x 10 -7BURASTERO ET AL.
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produced: one that is polyreactive and low affinity (Kd, 10" 5 moltliter) and the other
one that is monoreactive and relatively high affinity (Kd, 10" 7 mollliter). The poly-
reactive low affinity RFs are found in the B cell repertoire of both normal individ-
uals and patients with RA, whereas the monoreactive high affinity RFs have been
found, thus far, only in the B cell repertoire of RA patients. Along this line, it has
recently been reported that two-thirds of the monoclonal autoantibodies generated
from nonimmunized, viable motheaten C57BL16J autoimmune mice are polyreac-
tive and the remaining one-third are monoreactive (9).
PolyclonalB cell activation has been proposed as a possible mechanism to account
for production of autoantibodies in systemic autoimmune diseases (27, 28). Based
on this model, one would predict that the autoantibodies produced should have the
functionalfeatures ofthe anti-self antibodies found in healthy subject, i.e., polyreac-
tive and relatively low affinity for self-antigens. The present study shows that in pa-
tients with RA, polyclonal activation does occur, but is restricted to the CD5' B
cell subset. Moreover, most of the antibodies produced by CD5' B cells are poly-
reactive and low affinity, similar to those produced by CD5' B cells from normal
individuals. At variance with this polyclonalactivationmodel are the recent reports
by Shlomchik et al. (29, 30), suggesting that in MLR/Ipr autoimmune mice, a non-
random antigen-driven clonal selection is operative in generating autoantibodies to
IgG Fc fragment and ssDNA. The demonstration in the present study that RFs pro-
duced by some of the CD5'' B cells from RA patients are monoreactive and high
affinity, would fit with an antigen-driven clonal selection model (31). If this were
the case, one would predict that the V,, and V,, gene segments of the monoreactive
high affinity antibodies would harbor many more somatic mutations than the V.
and V,, gene segments coding for the polyreactive low affinity antibodies, which ap-
pear to be very close to unmutated "germline" genes (20, 32, and Sanz, et al., manu-
script submitted for publication). Sequencing the genes of both the monoreactive
high affinity and polyreactive low affinity RFs in RA patients, which is now in prog-
ress, should help resolve this issue.
It has been suggested that the number of the CD5' B cells in the circulation of
individuals with RA, may be influenced more by the genetic background than by
the expression or activity ofthe disease (33). A scenario that might relate these var-
ious observations is that individuals who have high numbers of proliferating CD5'
B cells may be at the greater risk of ultimately developing RA. A high number of
proliferating CD5' B cells would increase the likelihood of occasional cells under-
going somatic mutations (34) and producing monoreactive high affinity RFs (35).
These antibodies may be more important in the pathogenesis of RA than polyreac-
tive low affinity antibodies. Alongthese lines, no direct correlation has been found,
thus far, between the titer of RF in the serum of RA patients and the number of
circulating CD5' B cells (unpublished data). Long-term longitudinal studies on the
number of CD5' B cells, their state of activation, and the affinity constants of the
RFs they produce would be particularly useful in evaluating the role of CD5' B
cells in the pathogenesis of different stages of RA.
Summary
In patients with rheumatoid arthritis (RA), circulating CD5' B lymphocytes, but
not CD5" B lymphocytes, are increased in number and size, exist in an activated1990
￿
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state, spontaneously proliferate, and secrete Ig that binds to the Fc fragment of IgG.
By constructing continuous mAb-secreting cell lines from CD5+ B lymphocytes,
the properties and dissociation constants (Kd) of these antibodies were determined.
Two types ofrheumatoid factors (RFs) with discrete reactivities were produced. The
first type is polyreactive and binds with relatively low affinity (Kd, 10" 5 mol/liter)
to the Fc fragment ofIgG. These antibodies are similar to those produced by CD5'
B cells from healthy subjects. The second type of RF is monoreactive and binds
with higher affinity (Kd, 10' mol/liter) to the Fc fragment of IgG. These latter au-
toantibodies are produced by CD5' B cells of RA patients, but not healthy sub-
jects. Long-term longitudinal studies are needed to determine the role of these two
types of RFs in the pathogenesis of RA.
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